PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight
DelveInsight's PLK-1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging ...
Genentech buys Regor’s CDK inhibitors in $850m deal
Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
emjreviews.com10h
Genentech acquires Regor’s next-gen CDK inhibitor portfolio
Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...
Food Allergy Research & Education10h
FARE Announces Annual Food Allergy Summit, in Washington DC, October 18-20
Join over 14,000 individuals and families managing food allergies who are sharing their food allergy stories and making a ...
Pharmabiz19h
Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer
Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...